Séance plénière N^o 1 – COAST-TO-COAST RETINA CHECKUP PART 1 SURGERY
Modérateurs : Bernard Hurley, M.D., et Robert Gizicki, M.D.

15h30 Mot de bienvenue et remarques préliminaires

15h40 Vitreoretinal Surgical Video Session: “Masters of Disasters”
David Wong, M.D.
Q&A (inclus)

16h25 Vitreoretinal Surgery in Uveitis
Sunil Srivastava, M.D.

16h40 Q&A

16h45 Pearls in Pediatric Retina Surgery
Cynthia Qian, MD

16h51 Complex Vitreoretinal Surgery
Flavio Rezende, M.D., Ph.D.

16h57 Bacillary Layer Detachment in the Pathophysiology of Secondary Macular Hole in Fovea-off Rhegmatogenous Retinal Detachment
Isabela M. Melo, M.D.

17h03 Q&A

17h11 Efficacy and Safety of Proposed MYL-1701P Biosimilar Compared to Eylea® (Reference Aflibercept) in Diabetic Macular Edema: A Randomized, Double-masked, Phase 3 Equivalence Study (INSIGHT Study)
Susan B. Bressler, M.D.

17h17 2-Year Evaluation of Subretinal Fluid Drainage Techniques in Pars Plana Vitrectomy for Primary Rhegmatogenous Retinal Detachment
(ELLIPSOID-2 Study)
Aditya Bansal, M.D.

17h23 Lenses for Pars Plana Scleral Fixation
Amar Mannina, MD

17h29 Q&A

17h37 Session 1 Remarques finales
Co-présidents : Bernard Hurley, M.D., et Robert Gizicki, M.D.

18h00 Réception de bienvenue – Princes’ Gates Ballroom

7h00 PETIT-DÉJEUNER – Princes’ Gates Ballroom

7h30 SYMPOSIUM SATELLITE – Cinema Ground Floor

Séance plénière N^o 2 – AGE-RELATED MACULAR DEGENERATION & DIABETIC MACULAR EDEMA
Modérateurs : Varun Chaudhary, M.D., et Jason Noble, M.D.

8h30 Introduction à la Section 2

8h40 Reticular Pseudodrusen – A Critical Phenotype
Robyn Guymer, AM, Ph.D.

8h55 Q&A

9h02 Tyrosine Kinase Inhibition for nAMD Clinical Trial Studies
Carl Regillo, M.D.

9h17 Q&A

9h24 Early OCT Signs of Atrophy in AMD
Robyn Guymer, AM, Ph.D.

9h39 Q&A

9h46 Translating Clinical Trials to Practice in Geographic Atrophy
Sobha Sivaprasad, MBBS

10h01 Q&A

10h08 VOYAGER: An Innovative Real-world Study of Faricimab and the Port Delivery System with Ranibizumab in Patients with nAMD and DME
Robyn Guymer, AM, Ph.D.

10h23 Q&A

10h30 PAUSE – Princes’ Gates Ballroom Pre-function Area, 3^e étage
Session d'affiches

Séance plénière N^o 3 – Retinal Vascular Disease
Modérateurs : Bernard Hurley, M.D., et Robert Gizicki, M.D.

11h00 Introduction à la Session 3

11h05 Choice of Agent in CRVO
Sobha Sivaprasad, MBBS

11h15 Q&A

11h22 CRAO Management and CRAO Masquerades
Sunil Srivastava, M.D.

11h37 Q&A

11h44 Where Do We Place Biosimilars in Our DME Treatment Algorithm?
Sobha Sivaprasad, MBBS

12h00 Q&A

12h07 Discontinuous Versus Continuous Treatment for DME: Evidence Review and Evidence Generation
Varun Chaudhary, M.D.

12h22 Q&A

12h30 DÉJEUNER – Princes’ Gates Ballroom

13h15 SYMPOSIUM SATELLITE – Cinema Ground Floor

Séance plénière N^o 4 – Surgery
Modérateur : Bernard Hurley, M.D., et Wai-Ching Lam, M.D.

14h15 Introduction à la Session 4

14h20 Perfluorocarbon Liquid in Retinal Detachment Repair: Pearls and Pitfalls
Carl Regillo, M.D.

14h35 Q&A

14h42 Mila Oh Memorial Lecture: Diagnosis and Management of Diabetic Retinopathy in 2030
Sobha Sivaprasad, MBBS

14h57 Q&A

15h04 The Surgical Management of Inherited Retinal Diseases
Peter Kertes, M.D.

15h19 Q&A

15h26 Gene Therapy for Neovascular AMD and Diabetic Retinopathy
Carl Regillo, M.D.

15h41 Q&A

15h48 PAUSE – Princes’ Gates Ballroom Pre-function Area, 3^e étage
Session d'affiches

Séance plénière N^o 5 – Uveitis
Modérateurs : Phil Hooper, M.D., et Robert Gizicki, M.D.

16h15 Introduction à la Session 5

16h25 Masquerade Syndromes, New Treatment in Uveitis Imaging
Sunil Srivastava, M.D.

16h40 Q&A

16h47 Clinical and Imaging Pearls in Uveitis
Nupura Bakshi, M.D.

17h02 Q&A

17h15-18h00 SCR assemblée générale annuelle – Cinema Ground Floor

18h30 GALA – Princes’ Gates Ballroom

Isabela M. Melo, M.D. – Toronto, ON

• Posterior Hyaloid Discontinuity on Optical Coherence Tomography in Partial Posterior Vitreous Detachment and Vitreomacular Traction
• Impact of Baseline Morphological Stage on Post-operative Outcomes in Rhegmatogenous Retinal Detachment

Parnian Arjmand, M.D. – Toronto, ON

• Juxtafoveal Retinal Arterial Macroaneurysm: The Role of Ancillary Imaging

Amin Kherani, M.D. – Calgary, AB

• Intraocular foreign body injuries from a Calgary perspective – a retrospective case series

Carl Shen, M.D. – Hamilton, ON

• Intraretinal silicone oil migration: An under recognized OCT phenotype

Paola Oquendo, M.D. – Hamilton, ON

• Comparison of the Photoreceptor Mosaic Before and After Macular Hole Surgery with High Resolution Adaptive Optics Imaging
• Epiretinal Membrane and Associated Tractional Abnormalities Following Rhegmatogenous Retinal Detachment Repair

Hatim Batawi, M.D. – Toronto, ON

• Outer Retinal Hyperreflective Dots, A Potential Biomarker in Rhegmatogenous Retinal Detachment

Khaldon Abbas – Vancouver, BC

• Characteristics of No-show appointments at a multicenter retina subspeciality practice

Aurora Pecaku, M.D. – Toronto, ON

• Reattachment Rate with Pneumatic Retinopexy vs Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment with a Single Break in Detached Retina Only

Irina Sverdlichenko – Toronto, ON

• Macular Hole Associated Retinal Detachment in High Myopic Patients: Case series and Overview of a Novel Surgical Technique

Aaditeya Jhaveri – Toronto, ON

• Optical coherence tomography biomarkers as potential predictors for visual function and response to intravitreal therapy in diabetic macular edema: a review

Fowad Daud – Hamilton, ON

• Combined versus Sequential Pars Plana Vitrectomy and Phacoemulsification for Macular Hole and Epiretinal Membrane – A Systematic Review and Meta-Analysis

Milena Cioana – Toronto, ON

• Post-procedural endophthalmitis visual outcomes by microorganism: A systematic review and meta-analysis

Roche Symposium: Saturday, May 13, at 7:30 am

Title: The Retina Breakfast Club: “Moving the Needle” in Retinal Vascular Disease 

Moderator:
Nupura Bakshi, MD, FRCSC
Ophthalmologist, St. Joseph's Health Centre, Kensington Eye Institute, St. Michael’s Hospital, and Mount Sinai Hospital
Associate Professor, Department of Ophthalmology and Vision Sciences, University of Toronto

Panelists:
Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS
Deputy Director, Centre for Eye Research Australia
Professor of Surgery (Ophthalmology), University of Melbourne

Nirojini Sivachandran, MD, PhD, FRCSC
Vitreoretinal Surgeon, Toronto Retina Institute
Toronto, ON

Sobha Sivaprasad, MBBS, FRCS, FRCOphth
Medical Retina Consultant Ophthalmologist,
Moorfields Eye Hospital NHS Foundation Trust
Professor of Retinal Clinical Research
University College London

Overview:

The management and treatment of patients with retinal disease continues to progress in light of real-world outcomes. Recognizing these evidence-based treatment advances and considering how the latest clinical trials and upcoming innovative treatments are key to enhancing patient satisfaction and outcomes. The Retina Breakfast Club is “Moving the Needle” in Retinal Vascular Disease by providing an opportunity to reflect on the barriers and new strategies in providing care to nAMD and DME patients. Join us for an interactive evidence-based discussion to exchange these topics with an international and Canadian expert panel.

Learning Objectives:  

• To discuss the current rationale for nAMD/DME treatment and patient selection.
• To share strategies for nAMD/DME management from real-world practice.
• To explore the role of extending anti-VEGF treatments to reduce injection burden.

Bayer Symposium: Saturday, May 13, at 1:15 pm

Title: Advances in Retinal Disease Management

Keynote Speaker:
Sobha Sivaprasad, MBBS, FRCS, FRCOphth
Medical Retina Consultant Ophthalmologist,
Moorfields Eye Hospital,
NHS Foundation Trust Professor of Retinal Clinical Research,
University College London

Moderator:
Varun Chaudhary, MD, FRCSC
Professor of Surgery, McMaster University
Hamilton Regional Eye Institute, St. Joseph’s Healthcare

Panelists:
Michael Kapusta, MD, FRCSC
Associate Professor of Ophthalmology, McGill University
Jewish General Hospital, Montreal

Wai-Ching Lam, MD, FRCSC
Clinical Professor, Dept of Ophthalmology, University of British Columbia
Vancouver General Hospital, Vancouver

Overview:

The symposium will consist of a keynote presentation by Dr. Sivaprasad followed by a panel discussion with the Canadian faculty. For the keynote presentation Dr. Sivaprasad will review the current state of AMD & DME management, highlighting current outcomes, challenges, and unmet needs faced by physicians and patients. Dr. Sivaprasad will then review recent advances in the field of AMD & DME management, including emerging therapies, OCT home monitoring, fluid management, use of AI, and dosing regimens. The second part of the symposium will feature a panel discussion focusing on clinical pearls for the practical application of the recent data in Canadian clinical practice and how it can benefit Canadian physicians and patients.

Learning Objectives:  

• To review the latest data on advances in wAMD & DME treatment  
• To understand the different treatment approaches to wAMD & DME management

Apellis Symposium: Sunday, May 14, at 9:30 am

Title: In Sight: Exploring Advancements in Geographic Atrophy 

Moderator:
Caroline Baumal, MD
Chief Medical Officer, Apellis Pharmaceuticals, USA
Professor of Ophthalmology, New England Eye Center, Tufts Medical Center
Waltham, Massachusetts

Presenters:
Rishi Singh, MD
President, Cleveland Clinic Martin North and South hospitals
Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine

Stela Vujosevic, MD, PhD, FEBO
Head, Medical Retina Unit
University Eye Clinic, San Giuseppe Hospital
IRCCS MultiMedica
Milan, Italy

Overview:

Geographic atrophy (GA) is characterized by thinning and loss of the retinal pigment epithelium and concurrent atrophy of photoreceptors and the choriocapillaris that leads to progressive and irreversible loss of vision. GA accounts for 20% of all legal blindness attributed to AMD. Pegcetacoplan is a C3/C3b complement inhibitor which was studied in a broad GA population in two 24-month Phase 3 trials, OAKS and DERBY. An overview of the results of OAKS and DERBY will be presented. A case series from OAKS and DERBY will also be presented to explore the interplay between morphology and function in GA.

Learning Objectives:  

• To briefly review classification, pathogenesis, epidemiology, and burden of illness of GA
• To review the efficacy and safety of intravitreal pegcetacoplan in GA: 24-month results from the Phase 3 OAKS and DERBY trials
• To examine the convergence and divergence of morphology and function in GA through a review of OAKS and DERBY case studies of structural versus functional parameters, and to better understand how the heterogeneity of GA affects the interplay between them.